These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 26529014

  • 1. Acupoint injection of onabotulinumtoxin A for migraines.
    Hou M, Xie JF, Kong XP, Zhang Y, Shao YF, Wang C, Ren WT, Cui GF, Xin L, Hou YP.
    Toxins (Basel); 2015 Oct 30; 7(11):4442-54. PubMed ID: 26529014
    [Abstract] [Full Text] [Related]

  • 2. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis.
    Elkind AH, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R, BoNTA-024-026-036 Study Group.
    J Pain; 2006 Oct 30; 7(10):688-96. PubMed ID: 17018329
    [Abstract] [Full Text] [Related]

  • 3. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
    Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM, BoNTA-009 Study Group.
    Pain Med; 2007 Sep 30; 8(6):478-85. PubMed ID: 17716321
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin type a therapy in migraine: preclinical and clinical trials.
    Shao YF, Zhang Y, Zhao P, Yan WJ, Kong XP, Fan LL, Hou YP.
    Iran Red Crescent Med J; 2013 Oct 30; 15(10):e7704. PubMed ID: 24693369
    [Abstract] [Full Text] [Related]

  • 5. Onabotulinumtoxin Type A reconstitution with preserved versus preservative-free saline in chronic migraine (B-RECON). A randomised, double-blind trial.
    Zidan A, Hussaini S, Gibson S, Brooks G, Mejico L.
    Int J Clin Pract; 2020 Sep 30; 74(9):e13522. PubMed ID: 32350975
    [Abstract] [Full Text] [Related]

  • 6. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun 30; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 7. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
    Silberstein S, Mathew N, Saper J, Jenkins S.
    Headache; 2000 Jun 30; 40(6):445-50. PubMed ID: 10849039
    [Abstract] [Full Text] [Related]

  • 8. Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study.
    Millán-Guerrero RO, Isais-Millán S, Barreto-Vizcaíno S, Rivera-Castaño L, Rios-Madariaga C.
    Eur J Neurol; 2009 Jan 30; 16(1):88-94. PubMed ID: 19087155
    [Abstract] [Full Text] [Related]

  • 9. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr 30; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 10. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC, BoNTA-039 Study Group.
    Mayo Clin Proc; 2005 Sep 30; 80(9):1126-37. PubMed ID: 16178492
    [Abstract] [Full Text] [Related]

  • 11. Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial.
    Suzuki K, Iizuka T, Sakai F.
    Intern Med; 2007 Sep 30; 46(13):959-63. PubMed ID: 17603233
    [Abstract] [Full Text] [Related]

  • 12. OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study.
    Zidan A, Roe C, Burke D, Mejico L.
    J Clin Neurosci; 2019 Nov 30; 69():237-240. PubMed ID: 31327585
    [Abstract] [Full Text] [Related]

  • 13. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial.
    Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M, GSK1358820 Spasticity Study Group.
    J Neurol; 2010 Aug 30; 257(8):1330-7. PubMed ID: 20358216
    [Abstract] [Full Text] [Related]

  • 14. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
    Blumenfeld A.
    Headache; 2003 Sep 30; 43(8):853-60. PubMed ID: 12940806
    [Abstract] [Full Text] [Related]

  • 15. Botulinum toxin type A in post-stroke upper limb spasticity.
    Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M, GSK1358820 Spasticity Study Group.
    Curr Med Res Opin; 2010 Aug 30; 26(8):1983-92. PubMed ID: 20569068
    [Abstract] [Full Text] [Related]

  • 16. Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine.
    Bruloy E, Sinna R, Grolleau JL, Bout-Roumazeilles A, Berard E, Chaput B.
    Plast Reconstr Surg; 2019 Jan 30; 143(1):239-250. PubMed ID: 30589800
    [Abstract] [Full Text] [Related]

  • 17. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
    Blumenfeld AM, Schim JD, Chippendale TJ.
    Headache; 2008 Feb 30; 48(2):210-20. PubMed ID: 18047502
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, Alabdullatif A, Zhang X, Machado M, Einarson TR.
    Pharmacotherapy; 2009 Jul 30; 29(7):784-91. PubMed ID: 19558252
    [Abstract] [Full Text] [Related]

  • 19. Single-site botulinum toxin type a injection for elimination of migraine trigger points.
    Behmand RA, Tucker T, Guyuron B.
    Headache; 2003 Jul 30; 43(10):1085-9. PubMed ID: 14629244
    [Abstract] [Full Text] [Related]

  • 20. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
    Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C, European BoNTA Headache Study Group.
    Cephalalgia; 2007 Jun 30; 27(6):492-503. PubMed ID: 17428299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.